In a new note to investors today, an analyst has provided a rating update for the Healthcare company, CRH Medical (TSX: CRH). The company received a Buy rating from Canaccord Genuity’s analyst Richard Close, with a C$5 price target.
According to TipRanks.com, Close is a 5-star analyst with an average return of 14.2% and a 61.3% success rate. Close covers the Services sector, focusing on stocks such as Envision Healthcare, Hms Holdings Corp, and Evolent Health.
Read also: Here’s Why Teva Stock Tumbled Today
CRH Medical has an analyst consensus of Moderate Buy, with a price target consensus of C$5.25, which is a 17.4% upside from current levels. In a report issued on July 27, TD Securities also upgraded the stock to Buy with a C$5 price target.
.
The company has a one-year high of C$4.76 and a one-year low of C$1.86. Currently, CRH Medical has an average volume of 156.4K.
CRH Medical Corp. engages in the provision of gastroenterologists with innovative services and products for the treatment of gastrointestinal diseases. It offers CRH O’Regan System, which focuses on physician education, patient outcomes, and patient awareness. The company was founded in 2000 and is headquartered in Vancouver, Canada.
The company’s shares closed on Thursday at C$4.47, close to its 52-week high of C$4.76.
